Navigation Links
Prolexys Pharmaceuticals Initiates Phase 1 Study
Date:8/29/2007

Novel Agent Administered in First-In-Human Study to Cancer Patients

SALT LAKE CITY, Aug. 29 /PRNewswire/ -- Prolexys Pharmaceuticals, Inc. today announced that its first-in-humans Phase 1 study of PRLX 93936 has begun. This open-label trial is designed to evaluate the safety, pharmacokinetic and pharmacodynamic properties of PRLX 93936 in patients with advanced solid tumors. Study sites include TGen Clinical Research at Scottsdale Healthcare in Scottsdale, Arizona, and Tower Cancer Research Foundation in Beverly Hills, California. The first Phase 1 study will be a dose-escalating trial involving up to 36 patients.

"We are enthusiastic about our participation in the study of this interesting new agent with what appears to be a unique mechanism of action," said Dr. Daniel Von Hoff, Physician-in-Chief and Director of Clinical Research at TGen, and the principal investigator for the study at Scottsdale Healthcare. "Rarely have we seen pre-clinical anti-tumor effects that match those produced by PRLX 93936. We're very hopeful that this compound will have a therapeutic effect in patients with tumors that are non-responsive to existing therapeutic agents."

"The initiation of this Phase I clinical trial demonstrates our commitment to develop novel approaches to cancer therapies based on the company's proteomics technology platform," said David Clark, President and CEO of Prolexys.

"Based on the broad anti-cancer activity we have seen in pre-clinical models, we are looking forward to evaluating the potential anti-cancer activity in humans for this new drug candidate," stated Dr. Sudhir Sahasrabudhe, Prolexys' Chief Scientific Officer.

About PRLX 93936

PRLX 93936 is a structural analog of a compound called erastin, in-licensed by Prolexys from the MIT/ Whitehead Institute in January 2005. Erastin was identified as a potential anti-cancer therapeutic in a screen against cell lines engineered to differentially express several oncogenes (cancer genes), including activated RasV12 (Cancer Cell 3, 285-96, 2003). Extensive medicinal chemistry efforts at Prolexys resulted in the discovery of PRLX 93936, a small molecule that is approximately 100 times more potent and 1000 times more soluble than erastin. Application of the company's proprietary chemiproteomics discovery platform identified the mitochondrial outer membrane protein VDAC (Voltage Dependent Anion Channel) as a potential target of erastin (Nature 447: 864-868, 2007), and PRLX 93936.

PRLX 93936 was tested against a series of normal and tumor cell lines derived from tumors with dissimilar causative mutations, indicating potent and selective activity against a wide variety of tumors, many with activated Ras pathway. The compound showed robust tumor regression in a range of human tumor xenografts grown in immuno-compromised mice, including models of pancreatic (PANC-1), colon (DLD1), and ovarian (OVCAR5) cancers, and melanoma (SK-Mel-28), fibrosarcoma (HT-1080) and other solid tumors. PRLX 93936 produced efficacy ranging from tumor-growth inhibition to complete regression in a dose-dependent fashion.

About Prolexys

Prolexys Pharmaceuticals, Inc. is a privately held biopharmaceutical enterprise that discovers small molecules acting on novel targets. Its therapeutic focus is cancer. The Company's ability to identify and validate novel targets is driven by its technological leadership in the field of proteomics and the application of proteomics to drug discovery programs. For more information about Prolexys, please visit http://www.prolexys.com.


'/>"/>
SOURCE Prolexys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25,2016 FDA ... near-infrared Cellvizio platform for urological and surgical applications ... MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... milestone in the US with the 12 th ... Drug Administration (FDA). This new FDA clearance covers ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
(Date:5/25/2016)... According to market research "Global ... Demand Forecast to 2022 - Industry Insights by Type ... by P&S Market Research, the global insulin delivery device ... it is expected to grow at a CAGR of ... segment is expected to witness the fastest growth at ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 26, 2016 , ... Catalent Pharma Solutions, the leading global ... and global clinical supply services, today announced two key appointments and the opening ... and strategic growth plans in the Asia Pacific region. , Howard Kim has ...
(Date:5/26/2016)... CA (PRWEB) , ... May 26, 2016 , ... In an effort to provide hair ... available to both Snapchat users and those who do not use the app. Dr. Mohebi, ... his new page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... for eating disorders, is opening a brand new child and adolescent residential treatment ... and their families with even more specialized eating disorder treatment and access to ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... multitude of activities from daily practices, arts & crafts, discussions, and games all ... East-D’Anna and Christy Evans have combined backgrounds in kids’ yoga, collegiate sport yoga ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eugene Batelli, ... Along with his wonderful accolades and stellar patient reviews, Dr. Batelli continues to ... , Dr. Eugene Batelli is a highly trained Podiatric Surgeon who specializes in ...
Breaking Medicine News(10 mins):